Earth Science Tech, Inc. Announces Partnership with Bionatus to Help Manufacture, Distribute, & Continue Further R&D on Cannabis (CBD) Products

Hollywood, FL, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, and medical device research and development, announces a strategic partnership with the new Canadian division of Brazil’s Bionatus Pharmaceutical Laboratory.

The two companies will initially cooperate to improve two of Bionatus’ existing products that have been successful in the Brazilian market, and then launch them in the USA. Both products are in liquid form. 

Propovit is a spray with ingredients derived from honey. It is used to refresh the mouth and relieve sore throat symptoms.

The second product, BioToss is a syrup that helps in the treatment of respiratory disorders by facilitating the expectoration of phlegm and other secretions. This product contains Mikania glomerata extracts that have both bronchodilator and expectorant benefits.

Both Propovit and BioToss are compatible with ETST’s High Grade CBD-rich Hemp Oil. Under the agreement, ETST will be the exclusive provider of this critical component of the new, improved formulas. In addition, ETST will be the exclusive distributor of these products in the USA for a five-year period.

Dr. Michel Aube, ETST’s CEO & CSO updates with, “we have selected the research center that will conduct the in vitro assays to demonstrate the efficiency of the nutraceuticals in the ETST product pipeline which are based on the company’s International Provisory Patent Application. As recently announced, we will soon deliver the formulas to the Centre De Développement Bioalimentaire Du Québec Inc., (CDBQ) for mass formula conversion. Thereafter, the new partner that will test the products’ biological activity will be announced. We are also finalizing the logistics of the launch of the much-awaited MSN-2 medical device with its partner, Michel Gauthier, MD. That are on schedule for the anticipated Q1 2018 product launch. Doctors and Public Health Officials from many countries are waiting for the product to be released. The recent agreements with the communications agency Absolu, alongside the participation of Dr. Gauthier, will accelerate these final preparations.”

“This new partnership offers ETST a new distribution channel, specialized formulas to market, and remedies to those in need. I personally suffered from asthma as a child and took many pharmaceuticals with side effects to help with the symptoms. I know our current CBD oil has helped many with asthma based on many customer positive feedback but, now thanks to Dr. Michel Aube and the new partnership with Bionatus he has formed, we are now able to formulate a product specifically for asthmatics and offer an alternative to individuals struggling with asthma as I did as a child. I look forward on sharing updates on all of Dr. Aube’s projects as they progress and on many exciting achievements on our new KannaBidioid subsidiary, and product distribution very soon.” ended Nickolas S. Tabraue, ETST, president, director, and COO.

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. T To learn more please visit:

View ETST's accomplishments and reports on its High-Grade CBD Hemp Oil: (here)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.
To learn more please visit:

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.
To learn more please visit:

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it's unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.
Website coming soon:

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


Contact Data